Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy

Table 1

Reasons for discontinuation of anti-VEGF treatment using either Aflibercept or Ranibizumab among patients with neovascular age-related macular degeneration aged ≥90 years.

	Aflibercept ()	Ranibizumab ()	value
Death during follow-up, n (%)	7 (13)	9 (15)	0.809
Burdened by treatment/opted out of treatment, n (%)	6 (11)	10 (16)	0.434
Inactive CNV, dry macula, and referral of patient to the primary sector, n (%)	5 (9)	3 (5)	0.470
Treatment stopped due to development of a fibrotic/untreatable lesion, n (%)	6 (11)	11 (18)	0.314

values were calculated using the χ²-test for all categories, but inactive CNV, dry macula, and referral of patient to the primary sector was calculated using Fisher’s exact test due to groups with <5.